Technical Data
P4256-34F
Plasminogen Activator Inhibitor Type I (PAI-1)
Description:
Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator(uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer.

Applications:
Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications have not been tested.

Recommended Dilutions:
ELISA: Can be used as a coating antibody for uPA:PAI-1 complex ELISA.
Optimal dilutions to be determined by the researcher.

Hybridoma:
NCI-Ag 4/1 myeloma cells with spleen cells from Balb/c mice.

Culture Medium:
RPMI 1640 with 10% fetal calf serum

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. 
TypeIsotypeCloneGrade
MabIgG19B6Affinity Purified
SizeStorageShippingSourceHost
100ul-20°CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Partially purified human PAI-1
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 15mM sodium azide.
Specificity:
Recognizes human PAI-1. No crossreactivity is observed with PAI-2. No reactivity is observed with any other human plasma protein.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Andreasen PA (2007) PAI-1 - a potential therapeutic target in cancer. Current Drug Target 9:1030-1041. 2. Loskutoff DJ, Curriden SA, Hu G, Deng G (1999) Regulation of adhesion by PAI-1. APMIS 107:54-61. 3. Andreasen PA, Kjøller L, Christensen (1997) The urokinase plasminogen activator system in cancer metastasis. A review. Int J Cancer 2: 1-22. 4. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk acording to urokinase -type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 62: 4617-22. 5. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.Cancer Res 53:2513-2521.